New study points to supply chain disruptions if the FDA removes ineffective decongestant from the market

PITTSBURGH, Feb. 8, 2024 — In a new study of nasal decongestant purchasing patterns, researchers at the University of Pittsburgh School of Medicine found that phenylephrine remained the most popular choice year after year, despite decades of concerns over a lack of evidence supporting its effectiveness.

Published today in JAMA, the research letter points to a coming wave of supplychain disturbances if the Food and Drug Administration (FDA) moves to pull oral phenylephrine from the shelves, as recommended by an FDA advisory panel in 2023 that found the medication ineffective.

The researchers analyzed purchases of phenylephrine and pseudoephedrine—the only two nasal decongestants currently approved by the FDA—by pharmacies and major retail outlets. Between 2012 and 2021, American pharmacies purchased 19.8 billion units of phenylephrine products, compared to 13.2 billion units of pseudoephedrine products.

The researchers showed that pseudoephedrine is usually sold as a stand-alone product; phenylephrine, however, tends to be combined with several drugs and packaged as multi-symptom products. If the FDA opts to follow the advisory panel’s recommendation, most multi-symptom products will be pulled from the shelves, as there are still few pseudoephedrine-based alternatives on the market.

The study points to a need for continued reform of the over-the-counter drug review process, said lead author Timothy Anderson, M.D., M.A.S., a primary care physician, health services researcher and assistant professor of medicine at Pitt.

"The FDA needs to hold over-the-counter drugs to a standard of effectiveness similar to that of prescription drugs,” Anderson said. “A comparable pathway is needed for drugs that are sold over the counter as exists for post-approval monitoring of the risks and efficacy of prescription drugs. This will require a substantial investment in infrastructure to expand capacity.”

Other authors on the study were Katie J. Suda, Pharm.D., M.S. and Walid F. Gellad, M.D., M.P.H., both of Pitt; and Mina Tadrous, Pharm.D., Ph.D., of the University of Toronto.

This research was supported by the National Institute on Aging (K76AG074878) and the Canadian Institutes of Health Research (#202109).

##

About the University of Pittsburgh School of Medicine

As one of the nation’s leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition. Driven mainly by the School of Medicine and its affiliates, Pitt has ranked among the top recipients of funding from the National Institutes of Health since 1998. In rankings released by the National Science Foundation, Pitt is in the upper echelon of all American universities in total federal science and engineering research and development support.

Likewise, the School of Medicine is equally committed to advancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and to training highly skilled, compassionate clinicians and creative scientists well-equipped to engage in world-class research. The School of Medicine is the academic partner of UPMC, which has collaborated with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region’s economy. For more information about the School of Medicine, see www.medschool.pitt.edu.